<DOC>
	<DOCNO>NCT02730299</DOCNO>
	<brief_summary>This study open-label , control , multicenter , international , Phase III , randomize study transplantation NiCord速 versus transplantation one two unmanipulated , unrelated cord blood unit patient acute lymphoblastic leukemia acute myeloid leukemia , myelodysplastic syndrome chronic myeloid leukemia , require disease feature render eligible allogeneic transplantation .</brief_summary>
	<brief_title>Transplantation Ex Vivo Expanded , UCB-derived , Stem &amp; Progenitor Cells vs. Unmanipulated UCB HM Patients</brief_title>
	<detailed_description>Successful blood marrow transplantation ( BMT ) require infusion sufficient number hematopoietic stem/progenitor cell ( HSPCs ) , capable home bone marrow regenerate full array hematopoietic cell lineage early late repopulating ability timely fashion . A major drawback Umbilical Cord Blood ( UCB ) low stem cell dose available transplantation , compare mobilized peripheral blood ( PB ) bone marrow . This low stem cell dose compromise chance engraftment contributes delay kinetics neutrophil platelet recovery , well transplant outcome . The aim ex vivo expansion cord blood provide graft sufficient number cell rapid robust vivo neutrophil platelet produce potential enable successful transplantation . NiCord速 stem/progenitor cell-based product compose ex vivo expand allogeneic cell one entire unit UCB . NiCord速 utilize small molecule nicotinamide ( NAM ) , epigenetic approach inhibit differentiation increase migration , bone marrow ( BM ) home engraftment efficiency Hematopoietic Progenitor Cells ( HPC ) expand ex vivo culture . The chief aim study compare safety efficacy NiCord速 single ex-vivo expand cord blood unit transplantation unmanipulated cord blood unit transplantation patient hematological malignancy follow conditioning therapy .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Applicable disease criterion Patients must one two partially HLAmatched CBUs Backup stem cell source Adequate Karnofsky Performance score Sufficient physiological reserve Signed write informed consent HLAmatched donor able donate Prior allogeneic HSCT Other active malignancy Active uncontrolled infection Active/symptoms central nervous system ( CNS ) disease Pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>